KOSDAQ-listed ROKIT Healthcare was strong early on the 18th. Buying is seen gathering on news that ROKIT Healthcare's artificial intelligence (AI) kidney disease prediction solution will be officially launched in the United States next month.
As of 9:59 a.m., ROKIT Healthcare was trading at 117,200 won, up 18,200 won (18.38%) from the previous session. It rose to as high as 124,800 won intraday, setting a 1-year high.
The company said before the regular session opened that it completed certifications for entry into the U.S. market for the AI kidney disease prediction solution "AI Kidney" and signed a commercialization license-out (technology export) agreement. The solution will be officially launched in the United States in April.
A ROKIT Healthcare official said, "The core of this contract is a high royalty rate reaching 18%," adding, "A diagnostic royalty of about 50,000 won per user will be incurred, and it is expected to serve as a powerful revenue source for ROKIT Healthcare going forward."